A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

Adverse events (AE),Serious adverse events (SAE),Abnormal security check,Pharmacokinetics:Peak concentration (Cmax),Area Under the Concentration-Time Curve From 0 to Last Observation (AUC [0-t]),Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]),Time to reach maximum (peak) plasma concentration following drug administration (Tmax),Half-life (t1/2),Apparent volume of distribution(Vd/F),Apparent clearance (CLz/F),End elimination rate (λz),Residual area percentage of the TQC3927 (AUC_%Extrap),Mean residence time from zero to last measurable concentration (MRT0-t),Mean residence time from zero to infinity (MRT0-∞),Accumulated excretion of drugs in urine and feces (Aecum),Accumulated excretion of drugs in urine (Aeu,cum),Accumulated excretion of drugs in feces(Aef,cum),Renal clearance (CLr),Total drug excretion ratio in urine and feces (Fe%),Drug excretion ratio in urine (Fe%u),Drug excretion ratio in feces (Fe%f)

This is a dose escalation trial. The dosing regimen involves a single-dose study. This is a
 single-center, randomized, double-blind, placebo-controlled study to evaluate the safety,
 tolerability and pharmacokinetic characteristics of TQC3927 powder for inhalation in healthy
 adults subjects.